Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Mirati data underscore KRAS opportunity in colorectal cancer

Mirati’s latest KRAS inhibitor data point to a potential efficacy advantage in colorectal cancer

By Lauren Martz, Senior Editor
September 19, 2021 1:58 PM UTC

Colorectal cancer is the new battleground for the most advanced KRAS inhibitors, and Mirati’s latest data from ESMO leave the company in a very competitive position going into registrational studies. 

During a poster session at the European Society of Medical Oncology (ESMO) congress on Sunday, Mirati Therapeutics Inc. (NASDAQ:MRTX) reported a monotherapy metastatic colorectal cancer win for its KRAS G12C inhibitor adagrasib, and found combination with EGFR inhibitor cetuximab is potentially synergistic in the Phase I/II KRYSTAL-1 study...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Mirati Therapeutics Inc.